Breaking the Silence: New Tech Gives ICU Patients Their Voice Back

BALTIMORE, MD – March 16, 2026 – For the millions of patients admitted to an Intensive Care Unit (ICU) each year, the experience is often defined by a frightening and profound silence. The life-saving intubation tubes and tracheostomies that help them breathe simultaneously rob them of their voice, leaving them unable to express pain, ask questions, or connect with loved ones. Now, a groundbreaking study aims to break that silence.

Laronix, Inc., an Australian medical technology firm, has partnered with the Greater Baltimore Medical Center (GBMC) to launch an investigational study of MIRA Voice, a next-generation artificial larynx. The technology, which has already helped restore speech for patients with permanent voice loss, will now be tested for the first time as a potential solution for the temporary but traumatic voicelessness experienced in the ICU. The study represents a significant step toward addressing what many experts call a silent epidemic in modern healthcare.

The Silent Trauma of Critical Care

Each year, over six million people in the United States are admitted to an ICU, and up to 40% require mechanical ventilation, rendering them unable to speak. While clinicians focus on stabilizing their physical condition, patients often endure immense psychological distress. Studies have shown that the inability to communicate is frequently reported by ICU survivors as their most frustrating and terrifying experience.

This communication barrier is more than just an emotional burden; it's a critical safety issue. Patients unable to articulate their needs are up to three times more likely to suffer preventable adverse events. Frustration, panic, anxiety, and a sense of dehumanization are common. This trauma can have lasting effects, with research linking communication difficulties to higher rates of post-traumatic stress disorder (PTSD), depression, and anxiety among ICU survivors. One study found that over a fifth of survivors suffer from PTSD, with many more experiencing long-term psychological challenges.

Currently, communication relies on rudimentary methods: head nods, gestures, mouthing words, or painstakingly writing on a board—options that are often impossible for heavily sedated or physically weak patients. While higher-tech solutions like eye-tracking devices exist, they are not widely adopted and often require significant cognitive and physical effort.

"Voice loss is a significant issue in ICUs," said Bushra Lohrasbi, a speech-language pathologist at GBMC’s Milton J. Dance Jr. Head and Neck Center and the study's primary investigator. "This results in a considerable amount of time being spent by our clinicians trying to understand and communicate with patients." This frustrating guesswork consumes valuable time and can lead to delays in care and misinterpretations of a patient’s needs.

A Technological Answer to a Human Problem

Laronix's MIRA Voice offers a novel approach. Unlike traditional electrolarynx devices that produce a robotic tone, MIRA is an FDA-registered system designed to more closely mimic natural human speech. It functions using a computer-controlled artificial lung and synthetic vocal folds, generating customizable male and female voices that can be articulated by the user's mouth.

"This is the first study to explore the use of MIRA Voice, a next-generation artificial larynx, as a potential treatment for ICU voice loss," stated Mousa Ahmadi, PhD, Chief Operating Officer of Laronix. "ICU-related voice loss is a significant, untreated global health issue, and we believe MIRA can enable ICU patients to communicate in a critical care environment."

The technology is not just about producing sound; it's about restoring connection and autonomy. The investigational study, which will involve approximately 12 patients at GBMC, will assess the device's effectiveness in enabling patients to express immediate needs and even sustain casual conversation—a simple act that is profoundly important for mental well-being.

The data gathered will also fuel the next stage of innovation: MIRA Voice AI. This future product aims to use artificial intelligence to analyze a patient’s pre-illness voice recordings and generate a synthetic voice that is uniquely their own, a development that could further restore a patient’s sense of identity during a disorienting hospital stay.

A Partnership Built on Innovation

The collaboration between Laronix and GBMC is not new. It builds upon a partnership that began in 2024 when the Milton J. Dance Jr. Head and Neck Center became the first healthcare institution in the world to be certified to offer Laronix’s AVA Voice, a non-invasive solution for laryngectomy patients. That experience established a foundation of trust and expertise, making GBMC a natural fit for this pioneering ICU study.

The Dance Center is renowned for its comprehensive approach to rehabilitation, focusing on the physical, emotional, and psychological healing of patients with head and neck conditions. This patient-centered philosophy aligns perfectly with the goals of the MIRA Voice study.

For Laronix, the study marks a strategic expansion from a specialized market—patients with permanent voice loss from laryngectomies—to the much larger and critically underserved population of ICU patients. If successful, it could position the company's technology as a new standard of care in hospitals worldwide.

Redefining Efficiency and Safety in the ICU

The implications of restoring voice in the ICU extend beyond patient comfort. The press release highlights an estimate that addressing communication barriers could yield up to $1.4 billion in annual cost savings in the U.S. alone. This figure is supported by broader research suggesting that communication failures are a major driver of medical errors and increased healthcare costs. Some studies indicate that communication breakdowns are a factor in up to 70% of serious hospital errors and can add thousands of dollars to the cost of an individual patient's stay.

By enabling clear and direct communication, MIRA Voice could streamline clinical workflows, reduce the time nurses spend on interpretive guesswork, and allow for faster and more accurate diagnosis and treatment. "Technological advances, such as MIRA Voice, provide patients with more effective and convenient voice restoration tools and may potentially facilitate verbal communication, reduce the amount of time and frustration spent in miscommunication, and improve the overall efficiency and quality of care," Lohrasbi explained.

The study, expected to conclude by mid-2026, will specifically measure these improvements to the efficiency and workflow of ICU care teams, providing concrete data on the technology's systemic benefits.

As the trial begins, it carries the hope of millions who have experienced or will experience the isolating silence of a critical illness. By giving patients back their voice, this innovative technology has the potential not only to improve safety and efficiency but also to restore a fundamental piece of their humanity when they need it most. The results could usher in a new era of patient-centered critical care, where no patient has to suffer in silence.